Can inhibitor-resistant substitutions in the Mycobacterium tuberculosis β-lactamase BlaC lead to clavulanate resistance?

A biochemical rationale for the use of β-lactam-β-lactamase inhibitor combinations

Sebastian G. Kurz, Kerstin A. Wolff, Saugata Hazra, Christopher R. Bethel, Andrea M. Hujer, Kerri M. Smith, Yan Xu, Lee W. Tremblay, John S. Blanchard, Liem Nguyen, Robert A. Bonomo

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The current emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis calls for novel treatment strategies. Recently, BlaC, the principal β-lactamase of Mycobacterium tuberculosis, was recognized as a potential therapeutic target. The combination of meropenem and clavulanic acid, which inhibits BlaC, was found to be effective against even extensively drug-resistant M. tuberculosis strains when tested in vitro. Yet there is significant concern that drug resistance against this combination will also emerge. To investigate the potential of BlaC to evolve variants resistant to clavulanic acid, we introduced substitutions at important amino acid residues of M. tuberculosis BlaC (R220, A244, S130, and T237). Whereas the substitutions clearly led to in vitro clavulanic acid resistance in enzymatic assays but at the expense of catalytic activity, transformation of variant BlaCs into an M. tuberculosis H37Rv background revealed that impaired inhibition of BlaC did not affect inhibition of growth in the presence of ampicillin and clavulanate. From these data we propose that resistance to β-lactam-β-lactamase inhibitor combinations will likely not arise from structural alteration of BlaC, therefore establishing confidence that this therapeutic modality can be part of a successful treatment regimen against M. tuberculosis.

Original languageEnglish (US)
Pages (from-to)6085-6096
Number of pages12
JournalAntimicrobial Agents and Chemotherapy
Volume57
Issue number12
DOIs
StatePublished - 2013

Fingerprint

Lactams
Clavulanic Acid
Mycobacterium tuberculosis
Extensively Drug-Resistant Tuberculosis
meropenem
welan
Enzyme Assays
Ampicillin
Mycobacterium
Drug Resistance
Amino Acids
Therapeutics
Growth
In Vitro Techniques

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases
  • Medicine(all)

Cite this

Can inhibitor-resistant substitutions in the Mycobacterium tuberculosis β-lactamase BlaC lead to clavulanate resistance? A biochemical rationale for the use of β-lactam-β-lactamase inhibitor combinations. / Kurz, Sebastian G.; Wolff, Kerstin A.; Hazra, Saugata; Bethel, Christopher R.; Hujer, Andrea M.; Smith, Kerri M.; Xu, Yan; Tremblay, Lee W.; Blanchard, John S.; Nguyen, Liem; Bonomo, Robert A.

In: Antimicrobial Agents and Chemotherapy, Vol. 57, No. 12, 2013, p. 6085-6096.

Research output: Contribution to journalArticle

Kurz, Sebastian G. ; Wolff, Kerstin A. ; Hazra, Saugata ; Bethel, Christopher R. ; Hujer, Andrea M. ; Smith, Kerri M. ; Xu, Yan ; Tremblay, Lee W. ; Blanchard, John S. ; Nguyen, Liem ; Bonomo, Robert A. / Can inhibitor-resistant substitutions in the Mycobacterium tuberculosis β-lactamase BlaC lead to clavulanate resistance? A biochemical rationale for the use of β-lactam-β-lactamase inhibitor combinations. In: Antimicrobial Agents and Chemotherapy. 2013 ; Vol. 57, No. 12. pp. 6085-6096.
@article{35a13a9740bc43c5951f902f8c23cf95,
title = "Can inhibitor-resistant substitutions in the Mycobacterium tuberculosis β-lactamase BlaC lead to clavulanate resistance?: A biochemical rationale for the use of β-lactam-β-lactamase inhibitor combinations",
abstract = "The current emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis calls for novel treatment strategies. Recently, BlaC, the principal β-lactamase of Mycobacterium tuberculosis, was recognized as a potential therapeutic target. The combination of meropenem and clavulanic acid, which inhibits BlaC, was found to be effective against even extensively drug-resistant M. tuberculosis strains when tested in vitro. Yet there is significant concern that drug resistance against this combination will also emerge. To investigate the potential of BlaC to evolve variants resistant to clavulanic acid, we introduced substitutions at important amino acid residues of M. tuberculosis BlaC (R220, A244, S130, and T237). Whereas the substitutions clearly led to in vitro clavulanic acid resistance in enzymatic assays but at the expense of catalytic activity, transformation of variant BlaCs into an M. tuberculosis H37Rv background revealed that impaired inhibition of BlaC did not affect inhibition of growth in the presence of ampicillin and clavulanate. From these data we propose that resistance to β-lactam-β-lactamase inhibitor combinations will likely not arise from structural alteration of BlaC, therefore establishing confidence that this therapeutic modality can be part of a successful treatment regimen against M. tuberculosis.",
author = "Kurz, {Sebastian G.} and Wolff, {Kerstin A.} and Saugata Hazra and Bethel, {Christopher R.} and Hujer, {Andrea M.} and Smith, {Kerri M.} and Yan Xu and Tremblay, {Lee W.} and Blanchard, {John S.} and Liem Nguyen and Bonomo, {Robert A.}",
year = "2013",
doi = "10.1128/AAC.01253-13",
language = "English (US)",
volume = "57",
pages = "6085--6096",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "12",

}

TY - JOUR

T1 - Can inhibitor-resistant substitutions in the Mycobacterium tuberculosis β-lactamase BlaC lead to clavulanate resistance?

T2 - A biochemical rationale for the use of β-lactam-β-lactamase inhibitor combinations

AU - Kurz, Sebastian G.

AU - Wolff, Kerstin A.

AU - Hazra, Saugata

AU - Bethel, Christopher R.

AU - Hujer, Andrea M.

AU - Smith, Kerri M.

AU - Xu, Yan

AU - Tremblay, Lee W.

AU - Blanchard, John S.

AU - Nguyen, Liem

AU - Bonomo, Robert A.

PY - 2013

Y1 - 2013

N2 - The current emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis calls for novel treatment strategies. Recently, BlaC, the principal β-lactamase of Mycobacterium tuberculosis, was recognized as a potential therapeutic target. The combination of meropenem and clavulanic acid, which inhibits BlaC, was found to be effective against even extensively drug-resistant M. tuberculosis strains when tested in vitro. Yet there is significant concern that drug resistance against this combination will also emerge. To investigate the potential of BlaC to evolve variants resistant to clavulanic acid, we introduced substitutions at important amino acid residues of M. tuberculosis BlaC (R220, A244, S130, and T237). Whereas the substitutions clearly led to in vitro clavulanic acid resistance in enzymatic assays but at the expense of catalytic activity, transformation of variant BlaCs into an M. tuberculosis H37Rv background revealed that impaired inhibition of BlaC did not affect inhibition of growth in the presence of ampicillin and clavulanate. From these data we propose that resistance to β-lactam-β-lactamase inhibitor combinations will likely not arise from structural alteration of BlaC, therefore establishing confidence that this therapeutic modality can be part of a successful treatment regimen against M. tuberculosis.

AB - The current emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis calls for novel treatment strategies. Recently, BlaC, the principal β-lactamase of Mycobacterium tuberculosis, was recognized as a potential therapeutic target. The combination of meropenem and clavulanic acid, which inhibits BlaC, was found to be effective against even extensively drug-resistant M. tuberculosis strains when tested in vitro. Yet there is significant concern that drug resistance against this combination will also emerge. To investigate the potential of BlaC to evolve variants resistant to clavulanic acid, we introduced substitutions at important amino acid residues of M. tuberculosis BlaC (R220, A244, S130, and T237). Whereas the substitutions clearly led to in vitro clavulanic acid resistance in enzymatic assays but at the expense of catalytic activity, transformation of variant BlaCs into an M. tuberculosis H37Rv background revealed that impaired inhibition of BlaC did not affect inhibition of growth in the presence of ampicillin and clavulanate. From these data we propose that resistance to β-lactam-β-lactamase inhibitor combinations will likely not arise from structural alteration of BlaC, therefore establishing confidence that this therapeutic modality can be part of a successful treatment regimen against M. tuberculosis.

UR - http://www.scopus.com/inward/record.url?scp=84887464104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887464104&partnerID=8YFLogxK

U2 - 10.1128/AAC.01253-13

DO - 10.1128/AAC.01253-13

M3 - Article

VL - 57

SP - 6085

EP - 6096

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 12

ER -